Nkarta Appoints New CMO, Adds Director

Ticker: NKTX · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1787400

Nkarta, INC. 8-K Filing Summary
FieldDetail
CompanyNkarta, INC. (NKTX)
Form Type8-K
Filed DateJul 16, 2024
Risk Levelmedium
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001, $530,000
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, board-election, personnel-change

TL;DR

Nkarta brings in a new CMO and adds a director to the board.

AI Summary

On July 10, 2024, Nkarta, Inc. announced the appointment of Dr. James M. Robinson as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are included in the filing.

Why It Matters

These executive and board changes at Nkarta, Inc. could signal shifts in the company's strategic direction and leadership focus, particularly in its clinical development efforts.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer of Nkarta, Inc.?

Dr. James M. Robinson has been appointed as the new Chief Medical Officer of Nkarta, Inc.

Who has been elected to Nkarta, Inc.'s Board of Directors?

Ms. Jennifer L. Jones has been elected to Nkarta, Inc.'s Board of Directors.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is July 10, 2024.

What is Nkarta, Inc.'s principal executive office address?

Nkarta, Inc.'s principal executive office is located at 1150 Veterans Boulevard, South San Francisco, CA 94080.

What is Nkarta, Inc.'s telephone number?

Nkarta, Inc.'s telephone number is (925) 407-1049.

Filing Stats: 1,393 words · 6 min read · ~5 pages · Grade level 10.6 · Accepted 2024-07-16 06:30:13

Key Financial Figures

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued on July 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nkarta, Inc. Date: July 16, 2024 By: /s/ Alicia Hager Alicia J. Hager, J.D., Ph.D. Chief Legal Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing